email article Teplizumab got a reticent thumbs-up from FDA advisors for an indication in delaying progression of at-risk patients to clinical type 1 diabetes (T1D). The agency's Endocrinologic and Metabolic Drugs Advisory Committee on Thursday voted 10-7 that sufficient evidence of benefit outweighed the risks for this novel biologic. However, a number on both sides indicated how narrowly they had come to making the opposite decision. "I voted 'yes' but had my finger over the 'no' button for a long time," said Jack Yanovski, MD, PhD, chief of the Section on Growth and Obesity at the National Institute of Child Health and Human Development in Bethesda, Maryland.